Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
- Conditions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Registration Number
- NCT00936832
- Locations
- 🇫🇷
Hopital Ambroise Pare, Boulogne Billancourt, France
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Institut Català d'Oncologia
- Target Recruit Count
- 70
- Registration Number
- NCT00931450
- Locations
- 🇪🇸
Institut Catala D'Oncologia, l'Hospitalet de Llobregat, Spain
Sunitinib Malate in Refractory Germ Cell Tumors
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00912912
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00910039
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Salivary Gland Squamous Cell CarcinomaStage III Salivary Gland CancerStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the LarynxStage III Verrucous Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the Larynx
- Interventions
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00906360
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Decatur Memorial Hospital, Decatur, Illinois, United States
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 471
- Registration Number
- NCT00903175
- Locations
- 🇺🇸
University of California at Los Angeles Dept. of UCLA (3), Los Angeles, California, United States
🇺🇸Loyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3), Maywood, Illinois, United States
🇺🇸Billings Clinic Dept of Billings Clinic(2), Billings, Montana, United States
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 12
- Registration Number
- NCT00891878
- Locations
- 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸Graham Hospital, Canton, Illinois, United States
🇺🇸Illinois CancerCare - Havana, Havana, Illinois, United States
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00890747
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT00887575
- Locations
- 🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States
🇺🇸Florida Cancer Specialists North, Ft. Myers, Florida, United States
🇺🇸National Capital Clinical Research Consortium, Bethesda, Maryland, United States
A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 14
- Registration Number
- NCT00886132
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.